Patents by Inventor David M. Hockenberry

David M. Hockenberry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING Bcl-2 FAMILY MEMBER PROTEINS
    Publication number: 20090203770
    Abstract: The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding affinity for cytochrome B. Pharmaceutical uses of the agents and compositions include treating apoptosis-associated disease, such as neoplasia and drug resistance, are also disclosed.
    Type: Application
    Filed: June 25, 2007
    Publication date: August 13, 2009
    Applicant: Fred Hutchison Cancer Research Center
    Inventors: David M. Hockenberry, Julian A. Simon, Shie-Pon Tzung
  • Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins
    Patent number: 7241804
    Abstract: The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding affinity for cytochrome B. Pharmaceutical uses of the agents and compositions include treating apoptosis-associated disease, such as neoplasia and drug resistance, are also disclosed.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: July 10, 2007
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: David M. Hockenberry, Julian A. Simon, Shie-Pon Tzung